EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Impact of prostate cancer screening in European ancestry un‐affected men with germline DNA repair pathogenic variants

Vittorio Fasulo, Giuseppe Chiarelli, Giuseppe Garofano, Carla Barbara Ripamonti, Monica Barile, Paolo Bianchi, Emanuela Morenghi, Alessio Benetti, Muhannad Aljoulani, Alessio Finocchiaro, Marco Paciotti iD, Pier Paolo Avolio and 13 more

BJUI Compass · 2025-03 · 6 (3)

DOI: 10.1002/bco2.424 ↗

At a glance

Journal article in BJUI Compass, published online on 2025-01-31. Written by Vittorio Fasulo and 24 co-authors. Institution: Department of Biomedical Sciences Humanitas University Milan Italy. Cited 6 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: Associazione Italiana per la Ricerca sul Cancro.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Objective Prostate cancer (PCa) is a significant global health concern, ranking as the second most prevalent cancer among men worldwide. Genetic factors, particularly germline pathogenic variants (PVs) in DNA repair genes (DRGs), play a crucial role in PCa predisposition. Our study aimed to assess patients' adherence to a targeted PCa screening program targeting high‐risk individuals with DRG PVs and evaluate the potential reduction in biopsy and MRI rates by employing our screening protocol. Methods We conducted a prospective ongoing trial evaluating targeted PCa screening in men with documented PVs in DRGs. Screening involved annual assessment of medical history, physical examination, prostate‐specific antigen (PSA) testing, Prostate Health Index (PHI), and multiparametric magnetic resonance imaging (mpMRI) when indicated. Descriptive statistics were used to analyse patient characteristics, and adherence to screening was evaluated at three time points: baseline (T0), one year (T1), and two years (T2) from enrolment. Key Findings and Limitations A total of 101 high‐risk individuals were enrolled, with a median age of 52 years. Adherence to screening was high, with 72.3% of patients attending the first annual follow‐up (T1) and 100% attending the second follow‐up (T2). Despite elevated PSA levels in some patients, no PCa was detected during the study period. However, our screening protocol demonstrated the potential in reducing unnecessary biopsies and MRIs, particularly in patients with elevated PSA but low PHI values. Limitations include the ongoing nature of the study, small sample size, and lack of non‐carrier controls. Conclusions and Clinical Implications Our findings described a new PCa screening strategy integrated with genetic risk factors. The incorporation of PHI shows promise in improving the efficiency of diagnostic procedures while minimizing unnecessary interventions. High adherence among high‐risk individuals underscores the potential effectiveness of targeted screening programs.

Subjects

Author keywords

BRCA 1–2DNA‐repair gene variantgenetic riskprostatic neoplasmscreening

Authors and institutions

  • Department of Biomedical Sciences Humanitas University Milan Italy.
  • Department of Urology IRCCS-Humanitas Research Hospital Milan Italy.
  • Laboratory Analysis Unit IRCCS-Humanitas Research Hospital Rozzano MI Italy.
  • Medical Genetics and RNA Biology Laboratory, IRCCS-Humanitas Research Hospital Rozzano Milan Italy.

ORCID profiles: Marco Paciotti, Giovanni Lughezzani, Massimo Lazzeri

Funding

  • Associazione Italiana per la Ricerca sul Cancro

Cite

APA

Fasulo, V., Chiarelli, G., Garofano, G., Ripamonti, C. B., Barile, M., Bianchi, P., Morenghi, E., Benetti, A., Aljoulani, M., Finocchiaro, A., Paciotti, M., Avolio, P. P., Beatrici, E., Arena, P., Saita, A., Hurle, R., Maura, F., Da Rin, G., Asselta, R., …, & Lazzeri, M. (2025). Impact of prostate cancer screening in European ancestry un‐affected men with germline DNA repair pathogenic variants. BJUI Compass, 6(3). https://doi.org/10.1002/bco2.424

Vancouver

Fasulo V, Chiarelli G, Garofano G, Ripamonti CB, Barile M, Bianchi P, et al. Impact of prostate cancer screening in European ancestry un‐affected men with germline DNA repair pathogenic variants. BJUI Compass. 2025;6(3). doi:10.1002/bco2.424

BibTeX
@article{Fasulo2025,
  author = {Fasulo, Vittorio and Chiarelli, Giuseppe and Garofano, Giuseppe and Ripamonti, Carla Barbara and Barile, Monica and Bianchi, Paolo and Morenghi, Emanuela and Benetti, Alessio and Aljoulani, Muhannad and Finocchiaro, Alessio and Paciotti, Marco and Avolio, Pier Paolo and Beatrici, Edoardo and Arena, Paola and Saita, Alberto and Hurle, Rodolfo and Maura, Federica and Da Rin, Giorgio and Asselta, Rosanna and Capalbo, Anita and Soldà, Giulia and Casale, Paolo and Buffi, Nicolò Maria and Lughezzani, Giovanni and Lazzeri, Massimo},
  title = {Impact of prostate cancer screening in European ancestry un‐affected men with germline DNA repair pathogenic variants},
  journal = {BJUI Compass},
  year = {2025},
  volume = {6},
  number = {3},
  doi = {10.1002/bco2.424}
}
Start for free →